Noradrenaline and serotonin reuptake inhibition as clinical principles: A review of antidepressant efficacy

Acta Psychiatrica Scandinavica, Supplement

Volumn 101, Issue 402, 2000, Pages 28-36

  Humble, M ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Depression; Reboxetine; Selective noradrenaline reuptake inhibitors; Selective serotonin reuptake inhibitors; Tricyclic antidepressants

Indexed keywords

ANTIDEPRESSANT AGENT; BRAIN MONOAMINE; DESIPRAMINE; IMIPRAMINE; LOFEPRAMINE; MAPROTILINE; NORADRENALIN UPTAKE INHIBITOR; OXAPROTILINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; VILOXAZINE; ADRENERGIC RECEPTOR AFFECTING AGENT; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN; SEROTONIN;

DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; FEEDBACK SYSTEM; HUMAN; NEUROCHEMISTRY; NEUROTRANSMISSION; NORADRENERGIC SYSTEM; REVIEW; SEROTONINERGIC SYSTEM; CLINICAL TRIAL; METABOLISM;

ADRENERGIC UPTAKE INHIBITORS; ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS; DEPRESSIVE DISORDER; HUMANS; MONOAMINE OXIDASE INHIBITORS; NOREPINEPHRINE; SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

EID: 0034130015     PISSN: 00651591     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0447.2000.02605.x     Document Type: Review

References (94)

1. 1. BOYCE P, HADZI-PAVLOVIC D. Issues in classification: some historical aspects. In: PARKER G, HADZI-PAVLOVIC D, eds. Melancholia: a disorder of movement and mood. New York: Cambridge University Press, 1996:9-19.
2. 2. American Psychiatric Association. Diagnostic and statistical manual of mental disorder, 4th edn. WILLIAMS JBW, ed. Washington: American Psychiatric Association, 1994.
3. 3. World Health Organization. The ICD-10 classification of mental and behavioural disorders. Diagnostic criteria for research. Geneva: World Health Organisation, 1993:1-223.
4. 4. QUITKIN FM, MCGRATH PJ, STEWART JW et al. Atypical depression, panic attacks and response to imipramine and phenelzine. A replication. Arch Gen Psychiatry 1990;47:935-941.
5. 5. CORYELL W, ENDICOTT J, MASER JD, KELLER MB, AKISKAL HS. Long-term stability of polarity distinctions in the affective disorders. Am J Psychiatry 1995;152:385-390.
6. 6. THALÉN BE, KJELLMAN BF, MORKRID L, WIBOM R, WETTERBERG L. Light treatment in seasonal and nonseasonal depression. Acta Psychiatr Scand 1995;91:352-360.
7. 7. PARKER G, HADZI-PAVLOVIC D, eds. Melancholia: a disorder of movement and mood: a phenomenological and neurobiological review. New York: Cambridge University Press, 1996.
8. 8. SULLIVAN PF, KENDLER KS. Typology of common psychiatric syndromes: an empirical study. Br J Psychiatry 1998; 173:312-319.
9. 9. LOOMER HP, SANDERS JC, KLINE NS. A clinical and pharmacodynamic evaluation of iproniazid as a psychic energizer. Psychiatr Res Rep Am Psychiatr Assoc 1957;8:129-141.
10. 10. KUHN R. Über die Behandlung depressiver Zustände mit einem Iminodibenzylderivat (G 22355). Schweiz Med Wochenschr 1957;87:1135-1140.
11. 11. AXELROD J, WHITBY R, HERTTIG G. Effect of psychotropic drugs on the uptake of tritiated noradrenaline by tissues. Science 1961;133:383-384.
12. 12. SCHILDKRAUT JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965;122:509-522.
13. 13. COPPEN A. The biochemistry of affective disorders. Br J Psychiatry 1967;113:1237-1264.
14. 14. CARLSSON A, FUXE K, UNGERSTEDT U. The effect of imipramine on central 5-hydroxytryptamine neurons. J Pharm Pharmacol 1968;20:150-151.
15. 15. LAPIN P, OXENKRUG GF. Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect. Lancet 1969;1:132-136.
16. 16. TAYLOR DP, CARTER RB, EISON AS et al. Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. J Clin Psychiatry 1995;56:3-11.
17. 2 receptor antagonism in dysthymic disorder: a double blind placebo-controlled study with ritanserin. Acta Psychiatr Scand 1991;83:244-248.
18. 18. BERNSTEIN JG. Induction of obesity by psychotropic drugs. Ann NY Acad Sci 1987;499:203-215.
19. 19. NUTT D. Mirtazapine: pharmacology in relation to adverse effects. Acta Psychiatr Scand 1997;96:31-37.
20. 20. MONTGOMERY SA, JAMES D, MONTGOMERY DB. Pharmacological specificity is not the same as clinical selectivity. Psychopharmacol Ser 1987;3:179-183.
21. 21. TILLER JW, SCHWEITZER I, MAGUIRE KP, DAVIS B. Is diazepam an antidepressant? Br J Psychiatry 1989;155:483-489.
22. 22. WALDMEIER PC, BAUMANN P, GRENNGRASS PM, MAÎTRE L. Effects of clomipramine and other tricyclic antidepressants on biogenic amine uptake and turnover. Postgrad Med J 1976;52:33-39.
23. 23. HYTTEL J. Pharmacological characterisation of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmcaol 1994;9:19-26.
24. 24. SONNTAG A, ROTHE B, GULDNER J, YASSOURIDIS A, HOLSBOER F, STEIGER A. Trimipramine and imipramine exert different effects on sleep EEG and on nocturnal hormone secretion during treatment of major depression. Depression 1996;4: 1-13.
25. 25. ROBERTSON MM, TRIMBLE MR. Major tranquillisers used as antidepressants. A review. J Affect Disord 1982;4:173-193.
26. 26. ERIKSSON E, HUMBLE M. Serotonin in psychiatric pathophysiology: a review of data from experimental and clinical research. In: POHL R, GERSHON S, eds. Progress in basic and clinical pharmacology, vol. 3: Biological basis of psychiatric treatment. Basel: Karger, 1990:66-119.
27. 27. WILLNER P. Dopamine and depression: a review of recent evidence. I-III. Brain Res 1983;287:211-246.
28. 28. BROWN AS, GERSHON S. Dopamine and depression. J Neural Transm Gen Sect 1993;91:75-109.
29. 29. SVENSSON TH. Brain noradrenaline and the mechanisms of action of antdepressant drugs. Acta Psychiatr Scand 2000; 101(Suppl. 402):18-27.
30. 30. DILSAVER SC. Cholinergic mechanisms in affective disorders. Future directions for investigators. Acta Psychiatr Scand 1986;74:312-334.
31. 31. BARDEN N, REUL JM, HOLSBOER F. Do antidepressants stabilise mood through actions on the hypothalamic pituitary-adrenocortical system? Trends Neurosci 1995;18:6-11.
32. 32. EIRING A, SULSER F. Increased synaptic availability of norepinephrine following desipramine is not essential for increased in GR mRNA. J Neural Transm 1997;104:1255-1258.
33. 33. BADAWY AA, EVANS M. Inhibition of rat liver tryptophan pyrrolase activity and elevation of brain tryptophan concentration by acute administration of small doses of antidepressants. Br J Pharmacol 1982;77:59-67.
34. 34. SALTER M, HAZELWOOD R, POGSON CI, IYER R, MADGE DJ. The effects of a novel and selective inhibitor of tryptophan 2,3-dioxygenase on trytophan and serotonin metabolism in the rat. Biochem Pharmacol 1995;49:1435-1442.
35. 35. SKENE DJ, BOJKOWSKI CJ, ARENDT J. Comparison of the effects of acute fluvoxamine and desipramine administration on melatonin and cortisol production in humans. Br J Clin Pharmacol 1994;37:181-186.
36. 36. UVNÄS-MOBERG K, BJÖRKSTRAND E, HILLEGAART V, AHLENIUS S. Oxytocin as a possible mediator of SSRI-induced antidepressant effects. Psychopharmacology (Berlin) 1999;142: 95-101.
37. 37. SJÖQVIST F. A pharmacokinetic approach to the treatment of depression. Int Pharmacopsychiatry 1971;6:147-169.
38. 38. KORF J, VAN PRAAG HM. Amine metabolism in the human brain: further evaluation of the probenecid test. Brain Res 1971;35:221-230.
39. 39. MAAS JW. Biogenic amines and depression. Biochemical and pharmacological separation of two types of depression. Arch Gen Psychiatry 1975;32:1357-1361.
40. 40. ÅSBERG M, THORÉN P, TRASKMAN L, BERTILSSON L, RINGBERGER V. Serotonin depression: a biochemical subgroup within the affective disorders? Science 1976;191:478-480.
41. 41. VAN PRAAG HM. New evidence of serotonin-deficient depressions. Neuropsychobiology 1977;3:56-63.
42. 42. HOLLISTER LE, DAVIS KL, BERGER PA. Subtypes of depression based on excretion of MHPG and response to nortriptyline. Arch Gen Psychiatry 1980;37:1107-1110.
43. 43. ÅBERG-WISTEDT A, JOSTELL KG, ROSS SB, WESTERLUND D. Effects of zimelidine and desipramine on serotonin and noradrenaline uptake mechanisms in relation to plasma concentrations and to therapeutic effects during treatment of depression. Psychopharmacology 1981;74:297-305.
44. 44. ÅBERG-WISTEDT A. A double blind study of zimelidine, a serotonin uptake inhibitor, and desipramine, a noradrenaline uptake inhibitor, in endogenous depression. I. Clinical findings. Acta Psychiatr Scand 1982;66:50-65.
45. 45. ÅBERG-WISTEDT A. Comparison between zimelidine and desipramine in endogenous depression. A cross-over study. Acta Psychiatr Scand 1982;66:129-138.
46. 46. LINGJæRDE O, BRATFOS O, BRATLID T, HAUG JO. A double-blind comparison of zimelidine and desipramine in endogenous depression. Acta Psychiatr Scand 1983;68:22-33.
47. 47. NYSTRÖM C, HÄLLSTRÖM T. Comparison between a serotonin and a noradrenaline reuptake blocker in the treatment of depressed outpatients. A cross-over study. Acta Psychiatr Scand 1987;75:377-382.
48. 48. WHITE K, WYKOFF W, TYNESS LL, SCHNEIDER L, ZEMANSKY M. Fluvoxamine in the treatment of tricyclic-resistant depression. J Psychiatry Neurosci 1990;15:156-158.
49. 49. EMRICH HM, BERGER M, RIEMANN D, VON ZERSSEN D. Serotonin reuptake inhibition vs norepinephrine reuptake inhibition: a double-blind differential-therapeutic study with fluvoxamine and oxaprotiline in endogenous and neurotic depressives. Pharmacopsychiatry 1987;20:60-63.
50. 50. HAMILTON M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
51. 51. SZEGEDI A, WETZEL H, ANGERSBACH D et al. A double-blind study comparing paroxetine and maprotiline in depressed outpatients. Pharmacopsychiatry 1997;30:97-105.
52. 52. NOLEN WA, VAN DE PUTTE JJ, DIJKEN WA et al. Treatment strategy in depression. I. Non-tricyclic and selective reuptake inhibitors in resistant depression: a double-blind partial crossover study on the effects of oxaprotiline and fluvoxamine. Acta Psychiatr Scand 1988;78:668-675.
53. 53. Danish University Antidepressant Group. Citalopram: clinical effect profile in comparison with clomipramine, a controlled multicentre study. Psychopharmacology (Berlin) 1986;90:131-138.
54. 54. Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance but weaker antidepressant effect than clomipramine in a controlled multicentre study. J Affect Disord 1990;18: 289-299.
55. 55. ROOSE SP, GLASSMAN AH, ATTIA E, WOODRING S. Comparative efficacy of serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry 1994;151: 1735-1739.
56. 56. BURNS RA, LOCK T, EDWARDS DR et al. Predictors of response to amine-specific antidepressants. J Affect Disord 1995;35:97-106.
57. 57. GATTI F, BELLINI L, GASPERINI M, PEREZ J, ZANARDI R, SMERALDI E. Fluvoxamine alone in the treatment of delusional depression. Am J Psychiatry 1996;153:414-416.
58. 58. HALL SM, REUS VI, MUNOZ RF et al. Nortriptyline and cognitive-behavioural therapy in the treatment of cigarette smoking. Arch Gen Psychiatry 1998;55:683-690.
59. 59. PROCHAZKA AV, WEAVER MJ, KELLER RT et al. A randomized trial of nortriptyline for smoking cessation. Arch Intern Med 1998;158:2035-2039.
60. 60. GLASSMAN AH. Psychiatry and cigarettes. Arch Gen Psychiatry 1998;55:692-693.
61. 61. THORÉN P, ÅSBERG M, CRONHOLM B, JÖRNESTEDT L, TRÄSKMAN L. Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial. Arch Gen Psychiatry 1980;37:1281-1285.
62. 62. GOODMAN WK, PRICE LH, DELGADO PL et al. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Arch Gen Psychiatry 1990;47:577-585.
63. 63. ERIKSSON E, HEDBERG MA, ANDERSCH B, SUNDBALD C. The serotonin reuptake inhibitor paroxetine is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology 1995;12:167-176.
64. 64. EVANS L, KENARDY J, SCHNEIDER P, HOEY H. Effect of a selective serotonin uptake inhibitor in agoraphobia with panic attacks. A double-blind comparison of zimeldine, imipramine and placebo. Acta Psychiatr Scand 1986;73: 49-53.
65. 65. DEN BOER JA, WESTENBERG HG. Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder: a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 1988;3:59-74.
66. 66. MODIGH K, WESTBERG P, ERIKSSON E. Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial. J Clin Psychopharmacol 1992;12:251-261.
67. 67. GENTIL V, LOTUFO-NETO F, ANDRADE L et al. Clomipramine, a better reference drug for panic/agoraphobia. I. Effectiveness comparison with imipramine. J Psychopharmacol 1993;7:316-324.
68. 68. FAHY TJ, O'ROURKE D, BROPHY J, SCHAZMANN W, SCIASCIA S. The Galway study of panic disorder. I: Clomipramine and lofepramine in DSM III-R panic disorder: a placebo-controlled trial. J Affect Disord 1992;25:63-75.
69. 69. CLARK LA, WATSON D. Tripartite model of anxiety and depression: psychometric evidence and taxonomic implications. J Abnorm Psychol 1991;100:316-336.
70. 70. KATZ RJ, LOTT M, LANDAU P, WALDMEIER P. A clinical test of noradrenergic involvement in the therapeutic mode of action of an experimental antidepressant. Biol Psychiatry 1993;33:261-266.
71. 71. WONG EHF, GRAVEEL CR, SMITH MW. Pharmacological selectivity of reboxetine, a selective noradrenaline reuptake inhibitor (NRI). Poster presentation. American College of Neuropsychopharmacology, Hawaii, December 8-12, 1997.
72. 72. BOSC M, DUBINI A, POLIN V. Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale. Eur Neuropsychopharmacol 1997;7:S57-S70.
73. 73. MONTGOMERY SA. Reboxetine: additional benefits to the depressed patient. J Psychopharmacol 1997;11:S9-S15.
74. 74. DUBINI A, BOSC M, POLIN V. Do noradrenaline and serotonin differentially affect social motivation and behaviour? Eur Neuropsychopharmacol 1997;7:S49-S55.
75. 75. RICHELSON E, PFENNING M. Blockade of antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake. Eur J Pharmacol 1984;140:277-286.
76. 76. RIVA M, BRUNELLO N, ROVESCALLI AC et al. Effect of reboxetine, a new antidepressant drug, on the central noradrenergic system: behavioural and biochemical studies. Drug Dev 1989;1:243-253.
77. 77. BOLDEN-WATSON C, RICHELSON E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993;12:1023-1029.
78. 78. RIHELSON E, NELSON A. Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther 1984;230:64-102.
79. 79. CUSACK B, NELSON A, RICHELSON E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berlin) 1994;114:559-565.
80. 80. POTTER WZ, CALIL HM, EXTEIN I, MUSCETTOLA G, GOODWIN FK. Crossover study of zimelidine and desipramine in depression: evidence for amine specificity. Psychopharmacol Bull 1981;17:26-29.
81. 81. POTTER WZ, SCHEININ M, GOLDEN RN et al. Selective antidepressants and cerebrospinal fluid. Lack of specificity on norepinephrine and serotonin metabolites. Arch Gen Psychiatry 1985;42:1171-1177.
82. 82. HRDINA PD, LAPIERRE YD. Plasma levels of maprotiline and zimelidine and their relationship to clinical response in depressed patients. Ther Drug Monit 1986;8:400-406.
83. 83. DAHL LE, LUNDIN L, LE FEVRE HONORE P, DENCKER SJ. Antidepressant effect of femoxetine and desipramine and relationship to the concentration of amine metabolites in cerebrospinal fluid. A double-blind evaluation. Acta Psychiatr Scand 1982:66:9-17.
84. 84. MOON CA, VINCE M. Treatment of major depression in general practice: a double-blind comparison of paroxetine and lofepramine. Br J Clin Pract 1996;50:240-244.
85. 85. NATHAN RS, PERFL JM, POLLOCK BG, KUPFER DJ. The role of neuropharmacologic selectivity in antidepressant action: fluvoxamine versus desipramine. J Clin Psychiatry 1990;51: 367-372.
86. 86. ROTH D, MATTES J, SHEEHAN KH, SHEEHAN DV. A double-blind comparison of fluvoxamine, desipramine and placebo in outpatients with depression. Prog Neuropsychopharmacol Biol Psychiatry 1990;14:929-939.
87. 87. DE MENDOCA LIMA CA, VANDEL S, BONIN B, BECHTEL P, CARRON R. Maprotiline versus fluvoxamine: comparison of their effects on the hypothalamo hypophyseal-thyroid axis. Encéphale 1997;23:48-55.
88. 88. DE JONGHE F, SWINKELS J, TUYNMAN QH. Randomized double-blind study of fluvoxamine and maprotiline in treatment of depression. Pharmacopsychiatry 1991;24: 21-27.
89. 89. TIMMERMAN L, DE-BEURS P, TAN BK et al. A double-blind comparative clinical trial of citalopram vs maprotiline in hospitalised depressed patients. Int Clin Psychopharmacol 1987;2:239-253.
90. 90. BOUCHARD JM, DELAUNAY J, DELISLE JP et al. Citalopram versus maprotiline: a controlled, clinical multicenter trial in depressed patients. Acta Psychiatr Scand 1987;76:583-592.
91. 91. BOUCHARD JM, STRUB N, NII R. Citalopram and viloxazine in the treatment of depression by means of slow drop infusion. A double-blind comparative trial. J Affect Disord 1997;46:51-58.
92. 92. DE JONGHE F, RAVELLI DP, TUYMAN QH. A randomised double-blind study of fluoxetine and maprotiline in the treatment of major depression. Pharmacopsychiatry 1991; 24:62-67.
93. 93. MASSANA J, MÖLLER H-J, BURROWS GD, MONTENEGRO RM. Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 1999; 14:73-80.
94. 94. LOO H, BENKELFAT C, VANELLE JM et al. Urinary 3-methoxy, 4-hydroxyphenylethylene glycol and therapeutic response to maprotiline and indalpine in major depression. J Neural Transm 1986;66:47-58.